- Home
- NRXS vs EVAX Comparison
NRXS vs EVAX Comparison
Compare NRXS & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRXS | EVAX |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.7M | 42.7M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NRXS | EVAX |
|---|---|---|
| Price | $4.46 | $4.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $8.00 | ★ $12.33 |
| AVG Volume (30 Days) | ★ 899.5K | 113.5K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,362,320.00 | ★ $7,650,000.00 |
| Revenue This Year | $31.05 | $128.77 |
| Revenue Next Year | $137.61 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 36.89 | ★ 132.17 |
| 52 Week Low | $1.33 | $1.20 |
| 52 Week High | $6.20 | $12.15 |
Technical Indicators
Market Signals| Indicator | NRXS | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 76.30 | 41.55 |
| Support Level | $2.63 | $4.60 |
| Resistance Level | $4.70 | $5.22 |
| Average True Range (ATR) | 0.40 | 0.43 |
| MACD | 0.17 | -0.09 |
| Stochastic Oscillator | 92.75 | 9.20 |
Price Performance
Historical ComparisonAbout NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About EVAX Evaxion Biotech
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.